A
Alnylam Pharmaceuticals, Inc. (ALNY)
NMS – Real vaqt narxi. Valyuta: USD
292.03
+7.19 (2.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
292.03
+7.19 (2.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Alnylam Pharmaceuticals, Inc. Qo'shma Shtatlar, Evropa va xalqaro miqyosda ribonuklein kislotasi aralashuvi asosida terapevtik vositalarni kashf qiladi, ishlab chiqadi, ishlab chiqaradi va tijoratlashtiradi. Kompaniya irsiy transtiretin-mediatsiyalangan (hATTR) amiloidoz uchun ONPATTRO; ATTR va hATTR amiloidozi uchun AMVUTTRA; giperxolesterinemiya uchun Leqvio; A yoki B gemofiliya uchun Qfitlia; o'tkir jigar porfiriyasi uchun GIVLAARI; va birinchi turdagi birlamchi giperoksaluriyaga qarshi OXLUMO taklif etadi. Shuningdek, u 3-bosqich sinovida bir qator mahsulotlarni ishlab chiqadi, jumladan, ATTR amiloidozi uchun Nucresiran; gipertenziya uchun Zilebesiran; miyasteniya gravis, paroksismal nokturnal gemoglobinuriya va geografik atrofiya uchun Cemdisiran; va gepatit D virusi infektsiyalari uchun Elebsiran. Bundan tashqari, kompaniya 2-bosqich sinovida turli mahsulotlarni ishlab chiqmoqda, jumladan, metabolik disfunksiya bilan bog'liq steatohepatit uchun Rapirosiran; diabetik buyrak kasalligi uchun ALN-ANG3; 2-toifa diabet uchun ALN-4324; miya amiloid angiopatiyasi uchun Mivelsiran, shuningdek, Altsgeymer kasalligi uchun 1-bosqich sinovida; va qon ketishi buzilishlari uchun ALN-6400. Shuningdek, u 1-bosqich sinovida bir qator mahsulotlarni ishlab chiqadi, jumladan, semirish va vaznni boshqarish uchun ALN-2232; alkogolsiz yog'li jigar kasalligi uchun ALN-PNP; dislipidemiya uchun ALN-APOC3; metabolik disfunksiya bilan bog'liq steatohepatit uchun ALN-CIDEB; Huntington kasalligi uchun ALN-HTT02; Altsgeymer kasalligi uchun ALN-5288; SOD1 amiotrofik lateral skleroz uchun ALN-SOD; Parkinson kasalligi uchun ALN-SNCA; polisitemiya verasi uchun AG-236; paroksismal nokturnal gemoglobinuriya uchun ALN-CFB; gepatotsellyulyar karsinoma uchun ALN-BCAT; va sog'lom ko'ngillilar uchun ALN-4285, ALN-4915 va ALN-F1202. Kompaniya Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; va Ionis Pharmaceuticals, Inc. bilan hamkorlik qiladi. Alnylam Pharmaceuticals, Inc. 2002 yilda tashkil etilgan va uning shtab-kvartirasi Kembrijda, Massachusets shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Kevin Joseph Fitzgerald Ph.D. | Executive VP, Chief Scientific Officer and Head of Early Research & Early Development |
| Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board |
| Dr. Pushkal P. Garg M.D. | Executive VP & Chief Research & Development Officer |
| Dr. Yvonne L. Greenstreet M.B.A., M.D. | CEO & Director |
| Mr. Bryan Andrew Supran J.D. | Chief Legal Officer |
| Mr. Jeffrey V. Poulton M.B.A. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | 8-K | alny-20260430.htm |
| 2026-04-30 | 10-Q | alny-20260331.htm |
| 2026-04-06 | DEF 14A | alny-20260406.htm |
| 2026-03-04 | 8-K | alny-20260302.htm |
| 2026-02-12 | S-8 | alny2026forms-8.htm |
| 2026-02-12 | 10-K | alny-20251231.htm |
| 2026-01-12 | 8-K | alny-20260111.htm |
| 2025-12-11 | 8-K | d201569d8k.htm |
| 2025-12-03 | 8-K | alny-20251202.htm |
| 2025-10-30 | 10-Q | alny-20250930.htm |
| CFO & Executive VP |
| Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer |
| Mr. Timothy J. Maines | Chief Technical Operations & Quality Officer |
| Mr. Tolga Tanguler M.B.A. | Executive VP & Chief Commercial Officer |
| Ms. Christine Regan Akinc | Chief Corporate Communications Officer |